Confirmed
One controlled phase 3 trial met its main goal, and teriflunomide is approved for this use.
DHODH inhibition (pyrimidine synthesis): prevent or delay MS in early MS (CIS or RIS)
early MS (CIS or RIS) · DHODH inhibition (pyrimidine synthesis)
Two or more controlled phase 3 trials met their main goal, or one did and a medicine of this approach is approved for this use.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 618
How the verdict was reached
Supported in phase 3: One controlled phase 3 trial met its main goal, and teriflunomide is approved for this use.
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| TOPIC | Phase 3 | 618 | 2008 | Met its main goal | Counted |
Counted: 1. Will count later: 0. Not counted: 0.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as Confirmed
Related hypotheses
Assembled by software from public sources.